{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:53:32Z","timestamp":1769604812109,"version":"3.49.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clinthera.2019.06.005","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T09:27:25Z","timestamp":1563960445000},"page":"1798-1815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Short-term Evidence in Adults of Anorexigenic Drugs Acting in the Central Nervous System: A Meta-Analysis"],"prefix":"10.1016","volume":"41","author":[{"given":"Daniela","family":"Farah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Cunio Machado","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.06.005_bib1","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2017.03.107","article-title":"Morbidity and mortality associated with obesity","volume":"5","author":"Abdelaal","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clinthera.2019.06.005_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1024\/0300-9831.76.4.157","article-title":"Introductory lecture the epidemiology and determinants of obesity in developed and developing countries","volume":"76","author":"Shetty","year":"2006","journal-title":"Int J Vitam Nutr Res"},{"key":"10.1016\/j.clinthera.2019.06.005_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/ijerph14040435","article-title":"Economic burden of obesity: a systematic literature review","volume":"14","author":"Tremmel","year":"2017","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.clinthera.2019.06.005_bib4","series-title":"Cochrane Database of Systematic Reviews","article-title":"Psychological interventions for overweight or obesity","author":"Shaw","year":"2005"},{"key":"10.1016\/j.clinthera.2019.06.005_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev.nutr.21.1.323","article-title":"Successful weight loss maintenance","volume":"21","author":"Wing","year":"2001","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.clinthera.2019.06.005_bib6","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1161\/CIRCRESAHA.116.307591","article-title":"Treatment of obesity: weight\u00a0loss and bariatric surgery","volume":"118","author":"Wolfe","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2019.06.005_bib7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/1570161112666140423223529","article-title":"Cardiovascular effects of current and future anti-obesity drugs","volume":"12","author":"Comerma-Steffensen","year":"2014","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.clinthera.2019.06.005_bib8","doi-asserted-by":"crossref","DOI":"10.1590\/S1518-8787.2016050006208","article-title":"Safety and efficacy of fenproporex for obesity treatment: a systematic review","volume":"50","author":"Paumgartten","year":"2016","journal-title":"Rev Sa\u00fade P\u00fablica"},{"key":"10.1016\/j.clinthera.2019.06.005_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1590\/1806-9282.63.03.203","article-title":"Diethylpropion and mazindol: an end to the discussion?","volume":"63","author":"Lucchetta","year":"2017","journal-title":"Rev Assoc M\u00e9dica Bras"},{"key":"10.1016\/j.clinthera.2019.06.005_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2019.06.005_bib13","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1016\/j.clinthera.2019.06.005_bib14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.06.005_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.ijo.0801098","article-title":"A\u00a0clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity","volume":"24","author":"Fangh\u00e4nel","year":"2000","journal-title":"Int J Obes"},{"key":"10.1016\/j.clinthera.2019.06.005_bib16","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ijo.2013.225","article-title":"A\u00a0comparative study of five centrally acting drugs on the pharmacological treatment of obesity","volume":"38","author":"Suplicy","year":"2014","journal-title":"Int J Obes"},{"key":"10.1016\/j.clinthera.2019.06.005_bib17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/archpsyc.60.11.1109","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder","volume":"60","author":"Appolinario","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2019.06.005_bib18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ijo.2009.124","article-title":"A\u00a0randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects","volume":"33","author":"Cercato","year":"2009","journal-title":"Int J Obes"},{"key":"10.1016\/j.clinthera.2019.06.005_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/diacare.26.1.125","article-title":"A\u00a0randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin","volume":"26","author":"McNulty","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2019.06.005_bib20","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/jama.289.14.1805","article-title":"Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial","volume":"289","author":"Berkowitz","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2019.06.005_bib21","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1542\/peds.2006-2137","article-title":"Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study","volume":"120","author":"Daniels","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2019.06.005_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.3.5978.284","article-title":"Double-blind evaluation of mazindol in refractory obesity","volume":"3","author":"Smith","year":"1975","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2019.06.005_bib23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial","volume":"356","author":"James","year":"2000","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2019.06.005_bib24","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.fertnstert.2007.05.002","article-title":"Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial","volume":"89","author":"Lindholm","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.clinthera.2019.06.005_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18433\/J3388P","article-title":"Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients","volume":"13","author":"Derosa","year":"2010","journal-title":"J\u00a0Pharm Pharm Sci"},{"key":"10.1016\/j.clinthera.2019.06.005_bib26","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2337\/diacare.24.11.1957","article-title":"Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control","volume":"24","author":"Gokcel","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2019.06.005_bib27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1368-5031.2005.00568.x","article-title":"Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study: a study of the effects of sibutramine","volume":"59","author":"Wang","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2019.06.005_bib28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1067\/mhj.2001.117510","article-title":"Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia","volume":"142","author":"Dujovne","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2019.06.005_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/j.1550-8528.1998.tb00324.x","article-title":"Effects of sibutramine on resting metabolic rate and weight loss in overweight women","volume":"6","author":"Seagle","year":"1998","journal-title":"Obes Res"},{"key":"10.1016\/j.clinthera.2019.06.005_bib30","doi-asserted-by":"crossref","DOI":"10.1590\/S0066-782X2002000200006","article-title":"Effects of sibutramine on the treatment of obesity in patients with arterial hypertension","volume":"78","author":"Faria","year":"2002","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.clinthera.2019.06.005_bib31","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/BF02850222","article-title":"Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry","volume":"23","author":"Sara\u00e7","year":"2006","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2019.06.005_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-145-2-200607180-00005","article-title":"Effects of sibutramine treatment in obese adolescents: a randomized trial","volume":"145","author":"Berkowitz","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2019.06.005_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.numecd.2004.07.002","article-title":"Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects","volume":"15","author":"de Simone","year":"2005","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2019.06.005_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.jhh.1001299","article-title":"Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by \u03b2-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial","volume":"16","author":"Sramek","year":"2002","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.clinthera.2019.06.005_bib35","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial","volume":"160","author":"McMahon","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2019.06.005_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.ijo.0800540","article-title":"Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study","volume":"22","author":"Hanotin","year":"1998","journal-title":"Int J Obes Relat Metab Disord J Int Assoc Study Obes"},{"key":"10.1016\/j.clinthera.2019.06.005_bib37","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/sj.ejcn.1602172","article-title":"Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study","volume":"59","author":"Mathus-Vliegen","year":"2005","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.clinthera.2019.06.005_bib38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1185\/03007997309111712","article-title":"Long-term use of diethylpropion in obesity","volume":"1","author":"McKay","year":"1973","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2019.06.005_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1062-1458(01)00555-4","article-title":"J.\u00a0Long-term weight loss with sibutramine. A randomized controlled trial","volume":"11","author":"Wirth","year":"2002","journal-title":"ACC Curr J Rev"},{"key":"10.1016\/j.clinthera.2019.06.005_bib40","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2337\/diacare.26.9.2505","article-title":"One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial","volume":"26","author":"Redmon","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2019.06.005_bib41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.ijo.0801481","article-title":"Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial","volume":"25","author":"Hansen","year":"2001","journal-title":"Int J Obes"},{"key":"10.1016\/j.clinthera.2019.06.005_bib42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000047310","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of sibutramine\u00a0in obese hypertensive patients","volume":"94","author":"Hazenberg","year":"2000","journal-title":"Cardiology"},{"key":"10.1016\/j.clinthera.2019.06.005_bib43","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity","volume":"353","author":"Wadden","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.06.005_bib44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02850257","article-title":"Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension","volume":"20","author":"Fangh\u00e4nel","year":"2003","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2019.06.005_bib45","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00592-004-0158-7","article-title":"Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects","volume":"41","author":"Tankova","year":"2004","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clinthera.2019.06.005_bib46","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/clpt.1991.144","article-title":"Sibutramine in weight control: a dose-ranging, efficacy study","volume":"50","author":"Weintraub","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.06.005_bib47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1463-1326.2000.00071.x","article-title":"Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study","volume":"2","author":"Finer","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2019.06.005_bib48","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/oby.2007.175","article-title":"Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients","volume":"15","author":"Early","year":"2007","journal-title":"Obesity"},{"key":"10.1016\/j.clinthera.2019.06.005_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obes Res"},{"key":"10.1016\/j.clinthera.2019.06.005_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/oby.2000.10","article-title":"Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population","volume":"8","author":"Cuellar","year":"2000","journal-title":"Obes Res"},{"key":"10.1016\/j.clinthera.2019.06.005_bib51","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/jc.2004-0263","article-title":"Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study","volume":"90","author":"Godoy-Matos","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2019.06.005_bib52","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/000992286700600607","article-title":"Treatment of obesity in underprivileged adolescents: comparison of diethylpropion hydrochloride with placebo in a double-blind study","volume":"6","author":"Andelman","year":"1967","journal-title":"Clin Pediatr (Phila.)"},{"key":"10.1016\/j.clinthera.2019.06.005_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF02850181","article-title":"Use of sibutramine an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study","volume":"22","author":"Milano","year":"2005","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2019.06.005_bib54","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.clinthera.2006.05.008","article-title":"Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial","volume":"28","author":"Garc\u00eda-Morales","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.06.005_bib55","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.clinthera.2004.09.017","article-title":"Use of sibutramine in overweight adult Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"S\u00e1nchez-Reyes","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.06.005_bib56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1463-1326.2000.00081.x","article-title":"Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus","volume":"2","author":"Fujioka","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2019.06.005_bib57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2004-817934","article-title":"Weight reduction by sibutramine in obese subjects in primary care medicine: the S. A. T. Study","volume":"112","author":"Hauner","year":"2004","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.clinthera.2019.06.005_bib58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine","volume":"106","author":"Apfelbaum","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2019.06.005_bib59","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/CIRCULATIONAHA.106.625400","article-title":"Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) Study","volume":"115","author":"Scholze","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2019.06.005_bib60","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1210\/jc.2006-0264","article-title":"The effect of sibutramine on energy expenditure and body composition in obese adolescents","volume":"92","author":"Van Mil","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2019.06.005_bib61","first-page":"146","article-title":"Eficaciay seguridad de dos formulaciones de fenproporex de liberaci\u00f3n lenta como tratamiento de obesidad","volume":"16","author":"Zaragoza","year":"2005","journal-title":"Rev Mex Cardiol"},{"key":"10.1016\/j.clinthera.2019.06.005_bib62","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/bmj.1.5231.1009","article-title":"Diethylpropion in the treatment of \u2018refractory\u2019 obesity","volume":"1","author":"Seaton","year":"1961","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2019.06.005_bib63","first-page":"347","article-title":"Mazindol in obesity with known cardiac disease a clinical evaluation","volume":"2","author":"Bradley","year":"1974","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.clinthera.2019.06.005_bib64","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/j.1552-4604.1972.tb00246.x","article-title":"Mazindol, A new non-amphetamine anorexigenic agent","volume":"12","author":"Hadler","year":"1972","journal-title":"J\u00a0Clin Pharmacol New Drugs"},{"key":"10.1016\/j.clinthera.2019.06.005_bib65","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1464-5491.2002.00655.x","article-title":"Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy: original article","volume":"19","author":"Serrano-Rios","year":"2002","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2019.06.005_bib66","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1067\/mhj.2002.124403","article-title":"Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction","volume":"144","author":"Zannad","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2019.06.005_bib67","doi-asserted-by":"crossref","first-page":"317","DOI":"10.6061\/clinics\/2017(05)10","article-title":"Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients","volume":"72","author":"Lucchetta","year":"2017","journal-title":"Clinics"},{"key":"10.1016\/j.clinthera.2019.06.005_bib68","article-title":"Guidance for industry developing products for weight management","volume":"19","year":"2007","journal-title":"Weight Manag"},{"issue":"7 Pt 2","key":"10.1016\/j.clinthera.2019.06.005_bib69","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00012","article-title":"Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials","volume":"119","author":"Wadden","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2019.06.005_bib70","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity","volume":"353","author":"Wadden","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.06.005_bib71","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","article-title":"Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Padwal","year":"2003","journal-title":"Int J Obes"},{"key":"10.1016\/j.clinthera.2019.06.005_bib72","article-title":"Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Zhou","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinthera.2019.06.005_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007654.pub4","article-title":"Long-term effects of weight-reducing drugs in people with hypertension","author":"Siebenhofer","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2019.06.005_bib74","first-page":"S30","article-title":"Sibutramine\u2014a review of clinical efficacy","volume":"21","author":"Lean","year":"1997","journal-title":"Int J Obes Relat Metab Disord J Int Assoc Study Obes"},{"key":"10.1016\/j.clinthera.2019.06.005_bib75","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00002018-200326140-00004","article-title":"A\u00a0Benefit-risk assessment of sibutramine in the management of obesity","volume":"26","author":"Nisoli","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2019.06.005_bib76","series-title":"Goodman & Gilman's Pharmacological Basis of Therapeutics","year":"2011"},{"key":"10.1016\/j.clinthera.2019.06.005_bib77","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/oby.2003.152","article-title":"Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials","volume":"11","author":"Kim","year":"2003","journal-title":"Obes Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:16Z","timestamp":1758963136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819303327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0149291819303327"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.06.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term Evidence in Adults of Anorexigenic Drugs Acting in the Central Nervous System: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}